David Fabrizio

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Intratumoral heterogeneity and immunotherapy resistance: clinical implications

  Annals of Oncology · 2025-11-05 · 8 citations

• Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy

  Journal for ImmunoTherapy of Cancer · 2025-09-01 · 1 citations

• Fragmentomic-based algorithm to computationally predict tumor-somatic, germline, and clonal hematopoiesis variant origin in liquid biopsy

  The Journal of Liquid Biopsy · 2025-07-15 · 6 citations

• Abstract CT102: Exploring the tumor molecular landscape associated with<i>TMPRSS2-ERG</i>: A post hoc analysis from the phase 3 TALAPRO-2 study of first-line (1L) talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in metastatic castration-resistant prostate cancer (mCRPC)

  Cancer Research · 2025-04-25

• Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agents

  JTO Clinical and Research Reports · 2025-03-19 · 6 citations

• Evaluation of a variant origin prediction (VOP) algorithm to distinguish clonal hematopoiesis (CH) variants from tumor-derived variants and to predict metastatic castrate resistant prostate cancer (mCRPC) clinical responses.

  Journal of Clinical Oncology · 2025-02-10 · 1 citations

• Tumor mutational burden and survival on immune checkpoint inhibition in &gt;8000 patients across 24 cancer types

  Journal for ImmunoTherapy of Cancer · 2025-02-01 · 38 citations

• 1178 Association between polygenic risk for thyroid dysfunction, derived from tumor panel sequencing, immune-related thyroid toxicity and overall survival in ICI treated NSCLC patients

  Regular and Young Investigator Award Abstracts · 2024-11-01

• 35 The impact of treatment modalities on use of ctDNA as an early endpoint in aNSCLC trials

  Regular and Young Investigator Award Abstracts · 2024-11-01 · 1 citations

• Supplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerPreprint

  2024-09-13

• Supplementary Figure S8 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerPreprint

  2024-09-13

• Supplementary Figure S4 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerPreprint

  2024-09-13

• Supplementary Table S2 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer

  2024-09-13

• Supplementary Table S1 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer

  2024-09-13

• Supplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerPreprint

  2024-09-13

• Supplementary Table S2 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer

  2024-09-13

• Supplementary Figure S5 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerPreprint

  2024-09-13

• Data from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerPreprint

  2024-09-13

• Supplementary Figure S11 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerPreprint

  2024-09-13

• Supplementary Figure S7 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate CancerPreprint

  2024-09-13